Medisum Biotech Private Limited

Product Description:

Empagliflozin Tablets 25 mg (marketed as Empazose 25) are an oral anti-diabetic medication used for the treatment of type 2 diabetes mellitus. It belongs to the class of sodium-glucose co-transporter-2 (SGLT2) inhibitors, which help remove excess glucose from the body through urine by acting on the kidneys.

This mechanism not only improves blood sugar control but also provides added benefits for heart and kidney health in appropriate patients.

Key Benefits:

• Effectively lowers blood glucose levels
• Helps in weight management
• Supports reduction in blood pressure
• Lowers the risk of cardiovascular complications
• Offers renal (kidney) protection in certain conditions

Composition:

• Each film-coated tablet contains:
  • Empagliflozin 25 mg

Indications:

• Type 2 Diabetes Mellitus
• Heart failure (as advised by a doctor)
• Chronic kidney disease (in selected patients)

Product Description:

Empagliflozin Tablets 10 mg are an oral anti-diabetic medication used for the management of type 2 diabetes mellitus. It belongs to the class of sodium-glucose co-transporter-2 (SGLT2) inhibitors, which work by reducing glucose reabsorption in the kidneys, thereby promoting the excretion of excess glucose through urine.

This helps in improving glycemic control and also provides additional cardiovascular and renal benefits in patients with diabetes.

Key Benefits:

• Helps lower blood sugar levels effectively
• Supports weight reduction and blood pressure control
• Reduces risk of cardiovascular events in diabetic patients
• Provides kidney protection in certain cases

Composition:

• Each film-coated tablet contains:
  • Empagliflozin 10 mg

Indications:

• Type 2 Diabetes Mellitus
• Heart failure (as prescribed)
• Chronic kidney disease (in specific patients)

Product Description:

Empazose L-25 is a combination oral anti-diabetic medication containing Empagliflozin and Linagliptin. It is used for the effective management of type 2 diabetes mellitus in adults when single-drug therapy is not sufficient.

This dual-action formula works through complementary mechanisms—Empagliflozin helps remove excess glucose via urine, while Linagliptin enhances insulin secretion and reduces glucose production—resulting in improved overall glycemic control.

Key Benefits:

• Provides better blood sugar control through dual mechanism
• Reduces fasting and post-meal glucose levels
• Supports weight management
• Low risk of hypoglycemia when used appropriately
• Offers cardiovascular and metabolic benefits

Composition:

• Each film-coated tablet contains:
  • Empagliflozin 25 mg
  • Linagliptin 5 mg

Indications:

• Type 2 Diabetes Mellitus (when combination therapy is required)